ClinicalTrials.gov record
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
ClinicalTrials.gov ID: NCT03013998
Public ClinicalTrials.gov record NCT03013998. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
ClinicalTrials.gov public records Last synced May 8, 2026, 8:09 AM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Study identification
- NCT ID
- NCT03013998
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Beat AML, LLC
- Other
- Enrollment
- 3,000 participants
Conditions and interventions
Interventions
- AG-120 (BAML-16-001-S16) Drug
- AG-221 (BAML-16-001-S3) Drug
- AZD5153 (BAML-16-001-S10) Drug
- AZD5991 (BAML-16-001-S18) Drug
- Azacitidine (BAML-16-001-S12 Arm A) Drug
- Azacitidine (BAML-16-001-S12 Arm B) Drug
- Azacitidine (BAML-16-001-S16) Drug
- Azacitidine (BAML-16-001-S17) Drug
- Azacitidine (BAML-16-001-S18) Drug
- Azacitidine (BAML-16-001-S2) Drug
- Azacitidine (BAML-16-001-S24) Drug
- Azacitidine (BAML-16-001-S3) Drug
- Azacitidine (BAML-16-001-S4) Drug
- Azacitidine (BAML-16-001-S9) Drug
- BI 836858 (BAML-16-001-S2) Biological
- Cytarabine (BAML-16-001-S1) Drug
- Cytarabine (BAML-16-001-S6) Drug
- Daunorubicin (BAML-16-001-S1) Drug
- Daunorubicin (BAML-16-001-S6) Drug
- Decitabine (BAML-16-001-S14) Drug
- Decitabine (BAML-16-001-S5) Drug
- Decitabine (BAML-16-001-S8 Group 1) Drug
- Decitabine (BAML-16-001-S8 Group 2) Drug
- Entospletinib (BAML-16-001-S4) Drug
- Entospletinib (BAML-16-001-S5) Drug
- Entospletinib (BAML-16-001-S6) Drug
- Gilteritinib (BAML-16-001-S8 Group 1) Drug
- Gilteritinib (BAML-16-001-S8 Group 2) Drug
- Laboratory Biomarker Analysis Other
- Pevonedistat (BAML-16-001-S9) Drug
- SNDX-5613 (BAML-16-001-S17) Drug
- Samalizumab (BAML-16-001-S1) Biological
- TP-0903 (BAML-16-001-S14) Drug
- Venetoclax (BAML-16-001-S10) Drug
- Venetoclax (BAML-16-001-S12 Arm A) Drug
- Venetoclax (BAML-16-001-S12 Arm B) Drug
- Venetoclax (BAML-16-001-S17) Drug
- Venetoclax (BAML-16-001-S24) Drug
- Venetoclax (BAML-16-001-S8 Group 2) Drug
- ZE46-0134 (BAML-16-001-S21 Group 1) Drug
- ZE46-0134 (BAML-16-001-S21 Group 2) Drug
- ficlatuzumab (BAML-16-001-S24) Drug
Drug · Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2016
- Primary completion
- Nov 30, 2028
- Completion
- Nov 30, 2028
- Last update posted
- Dec 16, 2025
2016 – 2028
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | Completed |
| UCLA Ronald Reagan Medical Center | Los Angeles | California | 90095 | Recruiting |
| University of California, San Francisco | San Francisco | California | 94143 | Recruiting |
| University of Colorado | Denver | Colorado | 80203 | Completed |
| University of Florida Health Shands Cancer Hospital | Gainesville | Florida | 32608 | Completed |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | Completed |
| Emory University | Atlanta | Georgia | 30308 | Recruiting |
| University of Chicago | Chicago | Illinois | 60637 | Recruiting |
| University of Kansas Clinical Research Center | Fairway | Kansas | 66205 | Recruiting |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | Recruiting |
| Mayo Clinic Minnesota | Rochester | Minnesota | 55905 | Completed |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| UNC Hospitals, University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | Recruiting |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | Recruiting |
| Ohio State University | Columbus | Ohio | 43210 | Recruiting |
| Oregon Health & Science University | Portland | Oregon | 97239 | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Not yet recruiting |
| University of Texas Southwestern | Dallas | Texas | 75390 | Recruiting |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | Utah | 84112 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03013998, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2025 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03013998 live on ClinicalTrials.gov.